FDA investigates potential tumour risk following SMA gene therapies
The US Food and Drug Administration is investigating a potential risk of tumour formation associated with Zolgensma and Itvisma gene therapies for spinal muscular atrophy, following evidence of viral vector DNA integration into patients' genomes...








Latest Comment
All CommentThe EMERGE network: Next steps for responsible embryo model research
by Dr Nienke de Graeff and 5 others
An international network of scientists, ethicists, lawyers, regulators, philosophers and policymakers has set out a shared vision – and a programme of work – for the responsible study and use of stem-cell-based embryo models...
Genetic testing in donor conception: What should we test for, and what can the results tell us?
by Dr J Todd Spradlin
Dr J Todd Spradlin explains the different types of genetic testing that can be used prior to conception, and what they can – and can't – tell us...
Under the Influence: Fertility, Advertising and Social Media
by Dr Stephanie Santos Paulo
During National Fertility Awareness Week, PET's latest event discussed how advertising, apps, influencers and social media make it increasingly difficult to separate facts from misinformation...
At last: FDA wins permanent injunction against stem cell clinic group
by Dr Patrick Foong
Dr Patrick Foong covers the final chapter of a lengthy legal case opposing the FDA and a California clinic group proposing stem cell therapies...
A tribute to Dr Marta Shahbazi (1985-2026)
by Sarah Norcross and 1 others
The director and deputy director of PET pay tribute to Dr Marta Shahbazi – a prominent and inspiring figure in human embryo research, who was killed in last week's rail collision in Spain...